| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(90)92894-N |
| P698 | PubMed publication ID | 1978163 |
| P50 | author | Stephen Holgate | Q1547900 |
| P2093 | author name string | A Harris | |
| J Palmer | |||
| O P Twentyman | |||
| J P Finnerty | |||
| P433 | issue | 8727 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 1338-1342 | |
| P577 | publication date | 1990-12-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Protection against allergen-induced asthma by salmeterol | |
| P478 | volume | 336 |
| Q68315770 | A Single-dose Comparison of Inhaled Albuterol and Two Formulations of Salmeterol on Airway Reactivity in Asthmatic Subjects |
| Q37603596 | A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. |
| Q72996887 | A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study |
| Q39382492 | Allergen-induced airway inflammation and its therapeutic intervention |
| Q33785342 | Allergic inflammation in upper and lower airways |
| Q77130637 | An overview of nine clinical trials of salmeterol in an asthmatic population |
| Q35258478 | Anti-inflammatory drugs in the treatment of allergic disease |
| Q59685269 | Anti-inflammatory effects of long-acting beta-agonists in asthma |
| Q35873460 | Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro |
| Q53652556 | Asthma and anaphylaxis: a relevant model for chronic disease? An historical analysis of directions in asthma research. |
| Q43208952 | Asthma care in general practice |
| Q35530577 | Asthma pathogenesis and the implications for therapy in children |
| Q67514385 | Asthma: a follow up statement from an international paediatric asthma consensus group |
| Q43164722 | Beta 2 agonists and asthma |
| Q35626577 | Changes in psychosocial adjustment after renal transplantation |
| Q71340037 | Characterization of a primate model of asthma using anti-allergy/anti-asthma agents |
| Q41846220 | Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung |
| Q67525282 | Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma |
| Q67525284 | Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (2). Why beta-agonists should not be used regularly |
| Q41150250 | Do bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness? |
| Q46463753 | Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs |
| Q35533203 | Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects |
| Q42710116 | Effects of BRL 38227 on neurally-mediated responses in the guinea-pig isolated bronchus |
| Q42370005 | Effects of beta 2-adrenoceptor agonists on anti-IgE-induced contraction and smooth muscle reactivity in human airways |
| Q70907460 | Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction |
| Q45296274 | Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma |
| Q72380004 | Exercise-induced asthma and anaphylaxis |
| Q28369430 | Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism |
| Q36269382 | Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor |
| Q41494401 | Human late asthmatic reactions. |
| Q71864060 | Inhaled Salmeterol and Albuterol in Asthmatic Patients Receiving High-dose Inhaled Corticosteroids |
| Q35252017 | Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance? |
| Q41952800 | Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin |
| Q41089460 | Inhibitory effects of formoterol and terbutaline on the development of late phase skin reactions |
| Q74221057 | Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant? |
| Q40388175 | Long- versus short-acting beta 2-agonists. Implications for drug therapy |
| Q40433878 | Long-Acting Inhaled Beta Agonists |
| Q35266386 | Long-acting beta 2-agonists |
| Q24246441 | Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid |
| Q24247926 | Long-acting beta2-agonists for stable chronic asthma |
| Q42923617 | Measurement of airway hyperresponsiveness: new considerations |
| Q33599184 | Newer therapeutic agents for asthma |
| Q24678822 | Pharmacotherapy and airway remodelling in asthma? |
| Q35331126 | Pharmacotherapy of childhood asthma. An inflammatory disease |
| Q35627764 | Prevention of exercise induced asthma by inhaled salmeterol xinafoate |
| Q35277314 | Recent advances in asthma |
| Q35041919 | Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. |
| Q61892575 | Reproducibility of allergen-induced early and late asthmatic responses |
| Q35250822 | Risks versus benefits of inhaled beta 2-agonists in the management of asthma |
| Q43723756 | Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours |
| Q73398077 | Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics |
| Q34653402 | Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease |
| Q41563083 | Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma |
| Q34574302 | Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung |
| Q40713319 | Salmeterol: an inhaled beta 2-agonist with prolonged duration of action |
| Q57452393 | Structural insights into binding specificity, efficacy and bias of a βAR partial agonist |
| Q36516893 | The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta- adrenoceptor agonists |
| Q68018205 | The beta-agonist controversy: fact or fiction? |
| Q54942896 | The current debate concerning beta-agonists in asthma: a review. |
| Q67797337 | The effect of a beta 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen |
| Q34074328 | The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients |
| Q74501913 | The effect of salmeterol on human eosinophils is both stimulus- and response-dependent |
| Q38055384 | The pharmacological modulation of allergen-induced asthma. |
| Q40896104 | The relationship between inflammation and hyperreactivity of the airways in asthma |
| Q44969708 | The therapeutic potential of long-acting beta 2-adrenoceptor agonists in allergic inflammation |
| Q40520444 | Tolerance with beta 2-adrenoceptor agonists: time for reappraisal |
| Q83944078 | [Long-acting beta(2)-adrenoceptor agonists for asthma and COPD] |
Search more.